Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
ICU
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 convalescent plasma studies
00.250.50.7511.251.51.752+Libster (DB RCT)50%0.50 [0.09-2.65]death2/804/80Improvement, RR [CI]TreatmentControlBalcells (RCT)-247%3.47 [0.35-11.9]death5/282/30Korley (RCT)-396%4.96 [0.58-42.2]death5/2501/248Tau​2 = 0.74; I​2 = 47.5%Early treatment-93%1.93 [0.47-7.87]12/3587/358-93% improvementGharbharan (RCT)4%0.96 [0.25-2.41]death6/4311/43Improvement, RR [CI]TreatmentControlLi (RCT)35%0.65 [0.27-1.39]death8/5112/50Avendaño-Solà (RCT)88%0.12 [0.01-2.11]death0/384/43Agarwal (RCT)-7%1.07 [0.73-1.58]death34/23531/229Bajpai (RCT)-323%4.23 [0.43-41.6]death3/141/15AlQahtani (RCT)50%0.50 [0.05-5.08]death1/202/20Simonovich (RCT)4%0.96 [0.50-1.83]death25/22812/105Ray (RCT)33%0.67 [0.30-1.50]death10/4014/40Recovery Co.. (RCT)0%1.00 [0.93-1.07]death1,399/5,7951,408/5,763Bégin (RCT)-13%1.13 [0.88-1.45]death156/62569/313Tau​2 = 0.00; I​2 = 0.0%Late treatment-0%1.00 [0.94-1.07]1,642/7,0891,564/6,621-0% improvementAll studies-1%1.01 [0.90-1.13]1,654/7,4471,571/6,979-1% improvement13 convalescent plasma COVID-19 studiesc19early.com/cp Sep 24, 2021Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18Effect extraction pre-specifiedFavors conv. plasmaFavors control 00.250.50.7511.251.51.752+Libster (DB RCT)50%0.50 [0.09-2.65]2/804/80Improvement, RR [CI]TreatmentControlBalcells (RCT)-247%3.47 [0.35-11.9]5/282/30Korley (RCT)-396%4.96 [0.58-42.2]5/2501/248Tau​2 = 0.74; I​2 = 47.5%Early treatment-93%1.93 [0.47-7.87]12/3587/358-93% improvementGharbharan (RCT)4%0.96 [0.25-2.41]6/4311/43Improvement, RR [CI]TreatmentControlLi (RCT)35%0.65 [0.27-1.39]8/5112/50Avendaño-Solà (RCT)88%0.12 [0.01-2.11]0/384/43Agarwal (RCT)-7%1.07 [0.73-1.58]34/23531/229Bajpai (RCT)-323%4.23 [0.43-41.6]3/141/15AlQahtani (RCT)50%0.50 [0.05-5.08]1/202/20Simonovich (RCT)4%0.96 [0.50-1.83]25/22812/105Ray (RCT)33%0.67 [0.30-1.50]10/4014/40Recovery Co.. (RCT)0%1.00 [0.93-1.07]1,399/5,7951,408/5,763Bégin (RCT)-13%1.13 [0.88-1.45]156/62569/313Tau​2 = 0.00; I​2 = 0.0%Late treatment-0%1.00 [0.94-1.07]1,642/7,0891,564/6,621-0% improvementAll studies-1%1.01 [0.90-1.13]1,654/7,4471,571/6,979-1% improvement13 convalescent plasma COVID-19 mortality resultsc19early.com/cp Sep 24, 2021Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18Favors conv. plasmaFavors control 00.250.50.7511.251.51.752+Libster (DB RCT)67%0.33 [0.07-1.60]2/806/80Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment67%0.33 [0.07-1.60]2/806/8067% improvementAll studies67%0.33 [0.07-1.59]2/806/8067% improvement1 convalescent plasma COVID-19 ICU resultc19early.com/cp Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.38Favors conv. plasmaFavors control 00.250.50.7511.251.51.752+Korley (RCT)10%0.90 [0.64-1.26]hosp.51/25756/254Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment10%0.90 [0.64-1.26]51/25756/25410% improvementBajpai (RCT)25%0.75 [0.55-1.04]hosp. time14 (n)15 (n)Improvement, RR [CI]TreatmentControlAlQahtani (RCT)22%0.78 [0.57-1.07]hosp. time20 (n)20 (n)Tau​2 = 0.00; I​2 = 0.0%Late treatment23%0.77 [0.61-0.96]0/340/3523% improvementAll studies19%0.81 [0.67-0.97]51/29156/28919% improvement3 convalescent plasma COVID-19 hospitalization resultsc19early.com/cp Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.28Favors conv. plasmaFavors control 00.250.50.7511.251.51.752+Libster (DB RCT)50%0.50 [0.09-2.65]death2/804/80Improvement, RR [CI]TreatmentControlBalcells (RCT)-247%3.47 [0.35-11.9]death5/282/30Korley (RCT)-396%4.96 [0.58-42.2]death5/2501/248Tau​2 = 0.74; I​2 = 47.5%Early treatment-93%1.93 [0.47-7.87]12/3587/358-93% improvementGharbharan (RCT)4%0.96 [0.25-2.41]death6/4311/43Improvement, RR [CI]TreatmentControlLi (RCT)35%0.65 [0.27-1.39]death8/5112/50Avendaño-Solà (RCT)88%0.12 [0.01-2.11]death0/384/43Agarwal (RCT)-7%1.07 [0.73-1.58]death34/23531/229Bajpai (RCT)-323%4.23 [0.43-41.6]death3/141/15AlQahtani (RCT)50%0.50 [0.05-5.08]death1/202/20Simonovich (RCT)4%0.96 [0.50-1.83]death25/22812/105Ray (RCT)33%0.67 [0.30-1.50]death10/4014/40Recovery Co.. (RCT)0%1.00 [0.93-1.07]death1,399/5,7951,408/5,763Bégin (RCT)-13%1.13 [0.88-1.45]death156/62569/313Tau​2 = 0.00; I​2 = 0.0%Late treatment-0%1.00 [0.94-1.07]1,642/7,0891,564/6,621-0% improvementAll studies-1%1.01 [0.90-1.13]1,654/7,4471,571/6,979-1% improvement13 convalescent plasma COVID-19 serious outcomesc19early.com/cp Sep 24, 2021Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18Effect extraction pre-specifiedFavors conv. plasmaFavors control 00.250.50.7511.251.51.752+Li (RCT)76%0.24 [0.07-0.64]viral+4/2615/23Improvement, RR [CI]TreatmentControlAgarwal (RCT)28%0.72 [0.55-0.95]viral+56/17376/169Bajpai (RCT)32%0.68 [0.42-1.09]viral load14 (n)15 (n)Tau​2 = 0.09; I​2 = 59.2%Late treatment41%0.59 [0.37-0.92]60/21391/20741% improvementAll studies41%0.59 [0.37-0.92]60/21391/20741% improvement3 convalescent plasma COVID-19 viral clearance resultsc19early.com/cp Sep 24, 2021Tau​2 = 0.09; I​2 = 59.2%; Z = 2.31Favors conv. plasmaFavors control 00.250.50.7511.251.51.752+Libster (DB RCT)50%0.50 [0.09-2.65]death2/804/80Improvement, RR [CI]TreatmentControlBalcells (RCT)-247%3.47 [0.35-11.9]death5/282/30Korley (RCT)-396%4.96 [0.58-42.2]death5/2501/248Tau​2 = 0.74; I​2 = 47.5%Early treatment-93%1.93 [0.47-7.87]12/3587/358-93% improvementGharbharan (RCT)4%0.96 [0.25-2.41]death6/4311/43Improvement, RR [CI]TreatmentControlLi (RCT)35%0.65 [0.27-1.39]death8/5112/50Avendaño-Solà (RCT)88%0.12 [0.01-2.11]death0/384/43Agarwal (RCT)-7%1.07 [0.73-1.58]death34/23531/229Bajpai (RCT)-323%4.23 [0.43-41.6]death3/141/15AlQahtani (RCT)50%0.50 [0.05-5.08]death1/202/20Simonovich (RCT)4%0.96 [0.50-1.83]death25/22812/105Ray (RCT)33%0.67 [0.30-1.50]death10/4014/40Recovery Co.. (RCT)0%1.00 [0.93-1.07]death1,399/5,7951,408/5,763Bégin (RCT)-13%1.13 [0.88-1.45]death156/62569/313Tau​2 = 0.00; I​2 = 0.0%Late treatment-0%1.00 [0.94-1.07]1,642/7,0891,564/6,621-0% improvementAll studies-1%1.01 [0.90-1.13]1,654/7,4471,571/6,979-1% improvement13 convalescent plasma COVID-19 Randomized Controlled Trialsc19early.com/cp Sep 24, 2021Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18Effect extraction pre-specifiedFavors conv. plasmaFavors control 00.250.50.7511.251.51.752+Libster (DB RCT)50%0.50 [0.09-2.65]2/804/80Improvement, RR [CI]TreatmentControlBalcells (RCT)-247%3.47 [0.35-11.9]5/282/30Korley (RCT)-396%4.96 [0.58-42.2]5/2501/248Tau​2 = 0.74; I​2 = 47.5%Early treatment-93%1.93 [0.47-7.87]12/3587/358-93% improvementGharbharan (RCT)4%0.96 [0.25-2.41]6/4311/43Improvement, RR [CI]TreatmentControlLi (RCT)35%0.65 [0.27-1.39]8/5112/50Avendaño-Solà (RCT)88%0.12 [0.01-2.11]0/384/43Agarwal (RCT)-7%1.07 [0.73-1.58]34/23531/229Bajpai (RCT)-323%4.23 [0.43-41.6]3/141/15AlQahtani (RCT)50%0.50 [0.05-5.08]1/202/20Simonovich (RCT)4%0.96 [0.50-1.83]25/22812/105Ray (RCT)33%0.67 [0.30-1.50]10/4014/40Recovery Co.. (RCT)0%1.00 [0.93-1.07]1,399/5,7951,408/5,763Bégin (RCT)-13%1.13 [0.88-1.45]156/62569/313Tau​2 = 0.00; I​2 = 0.0%Late treatment-0%1.00 [0.94-1.07]1,642/7,0891,564/6,621-0% improvementAll studies-1%1.01 [0.90-1.13]1,654/7,4471,571/6,979-1% improvement13 convalescent plasma COVID-19 RCT mortality resultsc19early.com/cp Sep 24, 2021Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18Favors conv. plasmaFavors control 00.250.50.7511.251.51.752+Libster (DB RCT)50%0.50 [0.09-2.65]death2/804/80Improvement, RR [CI]TreatmentControlBalcells (RCT)-247%3.47 [0.35-11.9]death5/282/30Korley (RCT)-396%4.96 [0.58-42.2]death5/2501/248Tau​2 = 0.74; I​2 = 47.5%Early treatment-93%1.93 [0.47-7.87]12/3587/358-93% improvementGharbharan (RCT)4%0.96 [0.25-2.41]death6/4311/43Improvement, RR [CI]TreatmentControlLi (RCT)35%0.65 [0.27-1.39]death8/5112/50Avendaño-Solà (RCT)88%0.12 [0.01-2.11]death0/384/43Agarwal (RCT)-7%1.07 [0.73-1.58]death34/23531/229AlQahtani (RCT)50%0.50 [0.05-5.08]death1/202/20Simonovich (RCT)4%0.96 [0.50-1.83]death25/22812/105Ray (RCT)33%0.67 [0.30-1.50]death10/4014/40Recovery Co.. (RCT)0%1.00 [0.93-1.07]death1,399/5,7951,408/5,763Bégin (RCT)-13%1.13 [0.88-1.45]death156/62569/313Tau​2 = 0.00; I​2 = 0.0%Late treatment-0%1.00 [0.94-1.06]1,639/7,0751,563/6,606-0% improvementAll studies-0%1.00 [0.93-1.08]1,651/7,4331,570/6,964-0% improvement12 convalescent plasma COVID-19 peer reviewed trialsc19early.com/cp Sep 24, 2021Tau​2 = 0.00; I​2 = 1.3%; Z = 0.12Effect extraction pre-specifiedFavors conv. plasmaFavors control 00.250.50.7511.251.51.752+Libster (DB RCT)50%0.50 [0.09-2.65]death2/804/80Improvement, RR [CI]TreatmentControlLibster (DB RCT)50%0.50 [0.09-2.65]ventilation2/804/80Libster (DB RCT)67%0.33 [0.07-1.60]ICU2/806/80Libster (DB RCT)48%0.52 [0.29-0.94]progression13/8025/80Balcells (RCT)-247%3.47 [0.35-11.9]death5/282/30Balcells (RCT)-163%2.63 [0.43-9.10]ventilation5/282/30Balcells (RCT)-23%1.23 [0.56-1.89]progression13/2812/30Korley (RCT)-396%4.96 [0.58-42.2]death5/2501/248Korley (RCT)10%0.90 [0.64-1.26]hosp.51/25756/254Korley (RCT)6%0.94 [0.72-1.22]progression77/25781/254Gharbharan (RCT)4%0.96 [0.25-2.41]death6/4311/43Gharbharan (RCT)12%0.88 [0.49-1.60]no disch.43 (n)43 (n)Li (RCT)35%0.65 [0.27-1.39]death8/5112/50Li (RCT)15%0.85 [0.53-1.18]no improv.25/5229/51Li (RCT)76%0.24 [0.07-0.64]viral+4/2615/23Avendaño-Solà (RCT)88%0.12 [0.01-2.11]death0/384/43Avendaño-Solà (RCT)93%0.07 [0.00-1.19]progression0/387/43Avendaño-Solà (RCT)92%0.08 [0.00-1.40]progression0/386/43Agarwal (RCT)-7%1.07 [0.73-1.58]death34/23531/229Agarwal (RCT)-7%1.07 [0.73-1.58]progression44/23541/229Agarwal (RCT)1%0.99 [0.54-1.81]ventilation19/22719/224Agarwal (RCT)28%0.72 [0.55-0.95]viral+56/17376/169Bajpai (RCT)-323%4.23 [0.43-41.6]death3/141/15Bajpai (RCT)-114%2.14 [0.22-21.1]death2/141/15Bajpai (RCT)-221%3.21 [0.38-27.4]ventilation3/141/15Bajpai (RCT)25%0.75 [0.55-1.04]hosp. time14 (n)15 (n)Bajpai (RCT)32%0.68 [0.42-1.09]viral load14 (n)15 (n)AlQahtani (RCT)50%0.50 [0.05-5.08]death1/202/20AlQahtani (RCT)33%0.67 [0.22-2.01]ventilation4/206/20AlQahtani (RCT)22%0.78 [0.57-1.07]hosp. time20 (n)20 (n)Simonovich (RCT)4%0.96 [0.50-1.83]death25/22812/105Simonovich (RCT)19%0.81 [0.50-1.31]7-point status228 (n)105 (n)Ray (RCT)33%0.67 [0.30-1.50]death10/4014/40Recovery Co.. (RCT)0%1.00 [0.93-1.07]death1,399/5,7951,408/5,763Recovery Co.. (RCT)-1%1.01 [0.97-1.06]no disch.1,963/5,7951,941/5,763Bégin (RCT)-13%1.13 [0.88-1.45]death156/62569/313Bégin (RCT)-12%1.12 [0.86-1.46]death141/61463/307Bégin (RCT)-16%1.16 [0.94-1.43]int./death199/61486/307convalescent plasma COVID-19 outcomesc19early.com/cp Sep 24, 2021Favors conv. plasmaFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit